News & Updates

Treatment with single or multiple doses of ceftazidime-avibactam (CAZ-AVI) results in favourable clinical outcomes and is well tolerated in hospitalized neonates and young infants with suspected or confirmed bacterial infections, according to a phase IIa study presented at IDWeek 2023.

Bivalent COVID-19 vaccine conferred protection against SARS-COV-2 infection among children and adolescents aged 5–11 years, according to a recent study presented at IDWeek 2023.

The use of chikungunya virus-like particle vaccine (CHIKV VLP) results in significantly higher seroresponse rate* and superior immunogenicity in adolescents and adults compared with placebo, according to two pivotal phase III trials presented at IDWeek 2023.

In a real-world cohort, virologically suppressed HIV patients who switched from a prior regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were less likely to discontinue their regimen than those who switched to dolutegravir/lamivudine (DTG/3TC).

The respiratory syncytial virus (RSV) vaccine by GSK demonstrated sustained effectiveness of about 67 percent among adults 60 years or older across two full RSV seasons in a phase III study, says an infectious disease expert who reported findings at IDWeek 2023.

Use of proton pump inhibitor (PPI) appears to contribute to an increased risk of serious infections in children, as reported in a study.

A recent study recommends having a high index of suspicion for Pott’s puffy tumour (PPT), a rare complication of frontal sinusitis, among adolescents who present with prolonged headache or frontal swelling.